Your browser doesn't support javascript.
loading
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.
Candido, Juliana B; Morton, Jennifer P; Bailey, Peter; Campbell, Andrew D; Karim, Saadia A; Jamieson, Thomas; Lapienyte, Laura; Gopinathan, Aarthi; Clark, William; McGhee, Ewan J; Wang, Jun; Escorcio-Correia, Monica; Zollinger, Raphael; Roshani, Rozita; Drew, Lisa; Rishi, Loveena; Arkell, Rebecca; Evans, T R Jeffry; Nixon, Colin; Jodrell, Duncan I; Wilkinson, Robert W; Biankin, Andrew V; Barry, Simon T; Balkwill, Frances R; Sansom, Owen J.
Afiliação
  • Candido JB; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Morton JP; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • Bailey P; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • Campbell AD; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Karim SA; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Jamieson T; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Lapienyte L; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Gopinathan A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Clark W; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • McGhee EJ; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Wang J; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Escorcio-Correia M; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Zollinger R; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Roshani R; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Drew L; Bioscience, Oncology, iMED Biotech Unit, AstraZeneca, Boston, MA, USA.
  • Rishi L; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • Arkell R; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Evans TRJ; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • Nixon C; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK.
  • Jodrell DI; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Wilkinson RW; MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK.
  • Biankin AV; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • Barry ST; Bioscience, Oncology, iMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Balkwill FR; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Sansom OJ; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK. Electronic address: o.sansom@beatson.gla.ac.uk.
Cell Rep ; 23(5): 1448-1460, 2018 05 01.
Article em En | MEDLINE | ID: mdl-29719257
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most patients present with advanced metastatic disease. We reveal that macrophages are the dominant leukocyte population both in human PDAC stroma and autochthonous models, with an important functional contribution to the squamous subtype of human PDAC. We targeted macrophages in a genetic PDAC model using AZD7507, a potent selective inhibitor of CSF1R. AZD7507 caused shrinkage of established tumors and increased mouse survival in this difficult-to-treat model. Malignant cell proliferation diminished, with increased cell death and an enhanced T cell immune response. Loss of macrophages rewired other features of the TME, with global changes in gene expression akin to switching PDAC subtypes. These changes were markedly different to those elicited when neutrophils were targeted via CXCR2. These results suggest targeting the myeloid cell axis may be particularly efficacious in PDAC, especially with CSF1R inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Linfócitos T / Receptores de Fator Estimulador das Colônias de Granulócitos e Macrófagos / Modelos Imunológicos / Carcinoma Ductal Pancreático / Macrófagos / Proteínas de Neoplasias Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Linfócitos T / Receptores de Fator Estimulador das Colônias de Granulócitos e Macrófagos / Modelos Imunológicos / Carcinoma Ductal Pancreático / Macrófagos / Proteínas de Neoplasias Idioma: En Ano de publicação: 2018 Tipo de documento: Article